SUBSEQUENT EVENTS	9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS Proposed Acquisition by Alexion Pharmaceuticals, Inc. The description of the Merger Agreement with Alexion in Note 1 in the accompanying notes to our unaudited consolidated financial statements is incorporated by reference hereto. A&R CANbridge Agreement On October 3, 2022, the Company and CANbridge entered into the Amended and Restated Exclusive Research Collaboration, License and Option Agreement (the “A&R CANbridge Agreement”), dated as of October 2, 2022, which amends the Original CANbridge Agreement. Under the A&R CANbridge Agreement, the Candidate Options and the LB-001 Option were removed as mutually agreed by both parties. Further, in connection with the Fabry and Pompe License, the A&R CANbridge Agreement grants CANbridge a non-exclusive license to certain Company intellectual property rights related to manufacturing for the Fabry and Pompe programs. Additionally, under the A&R CANbridge Agreement, the CANbridge Research Plan was amended to reflect that the full transfer of the technology pertaining to the Fabry and Pompe programs to CANbridge was effective as of October 31, 2022. Under the A&R CANbridge Agreement, CANbridge does not have an obligation to pay or reimburse additional research expenses. Under the A&R CANbridge Agreement, the Company will be eligible to receive clinical, regulatory and commercial milestone payments of up to $224.5 million in the aggregate (assuming one product for each indication). In accordance with the removal of the two additional Candidate Options and LB-001 Option, milestones related thereto were removed in the A&R CANbridge Agreement. Under the A&R CANbridge Agreement, the tiered royalty rates payable to the Company will range from low single digit to mid-single digit rates. Under the A&R CANbridge Agreement, LogicBio and CANbridge will negotiate a product reversion agreement in good faith in the event of a termination of the A&R CANbridge Agreement under certain circumstances.

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2022

13. SUBSEQUENT EVENTS

Proposed Acquisition by Alexion Pharmaceuticals, Inc.

The description of the Merger Agreement with Alexion in Note 1 in the accompanying notes to our unaudited consolidated financial statements is incorporated by reference hereto.

A&R CANbridge Agreement

On October 3, 2022, the Company and CANbridge entered into the Amended and Restated Exclusive Research Collaboration, License and Option Agreement (the “A&R CANbridge Agreement”), dated as of October 2, 2022, which amends the Original CANbridge Agreement.

Under the A&R CANbridge Agreement, the Candidate Options and the LB-001 Option were removed as mutually agreed by both parties. Further, in connection with the Fabry and Pompe License, the A&R CANbridge Agreement grants CANbridge a non-exclusive license to certain Company intellectual property rights related to manufacturing for the Fabry and Pompe programs. Additionally, under the A&R CANbridge Agreement, the CANbridge Research Plan was amended to reflect that the full transfer of the technology pertaining to the Fabry and Pompe programs to CANbridge was effective as of October 31, 2022. Under the A&R CANbridge Agreement, CANbridge does not have an obligation to pay or reimburse additional research expenses.

Under the A&R CANbridge Agreement, the Company will be eligible to receive clinical, regulatory and commercial milestone payments of up to $224.5 million in the aggregate (assuming one product for each indication). In accordance with the removal of the two additional Candidate Options and LB-001 Option, milestones related thereto were removed in the A&R CANbridge Agreement. Under the A&R CANbridge Agreement, the tiered royalty rates payable to the Company will range from low single digit to mid-single digit rates. Under the A&R CANbridge Agreement, LogicBio and CANbridge will negotiate a product reversion agreement in good faith in the event of a termination of the A&R CANbridge Agreement under certain circumstances.

LogicBio Therapeutics, Inc. 10-Q